Skip to main content
SpringerLink
Log in

Future Directions in the Therapy of Lung Cancer

  • Conference paper
Current Topics in Lung Cancer

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 40 Accesses

Abstract

Lung cancer is the leading cause of cancer deaths in Australia and in other developed countries with an age-standardised mortality of 43 per 100,000 for men and 11 per 100,000 for women [1]. The outcome for 2090 inoperable lung cancer patients presenting to the Peter MacCallum Cancer Institute, Melbourne, reveals a median survival of only 27 weeks. There has been no improvement in survival over the last 20 years. Cox regression models of prognostic factors for patients with inoperable disease confirm that patients with good performance status, no distant metastasis and with prior surgery survive significantly longer. However, even in patients with Eastern Cooperative Oncology Group (ECOG) performance status 0, the median survival is only 17 months.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Giles G, Armstrong BK, Smith LR (eds) Cancer in Australia 1982. National Cancer Statistics Clearing House. Scientific Publication No 1, 1987.

    Google Scholar 

  2. Spielgelman D, Maurer LH, Ware JH, Perry MC, Chatrinian P, Conris R, Eaton W, Zimmer B, Greem M: Prognostic factors in small cell carcinoma of the lung: an analysis of 1521 patients. J Clin Oncol 1989 (7):344–354.

    Google Scholar 

  3. Sierocki JS, Hilaris BS, Hopfan S, Martini V, Barton D, Gobey RB and Wittes RE: Cisdichlorodiammeplatinum (II) and VP16-213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 1979 (63): 9–10.

    Google Scholar 

  4. Evans WK, Osobe D, Feld R, Shepherd FA, Bagos MJ and DeBoer G: Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small cell lung cancer. J Clin Oncol 1985 (3):65–71.

    PubMed  CAS  Google Scholar 

  5. Evans WK, Fed R, Murray N et al: Superiority of alternating non-cross resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 1987 (107): 451–458.

    PubMed  CAS  Google Scholar 

  6. Cavalli F, Sontag RW, Jungi F, Senn HJ, Brunner KW: VP 16-213. Monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat. Rep 1978 (62):473–475.

    CAS  Google Scholar 

  7. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989 (7): 1333–1340.

    PubMed  CAS  Google Scholar 

  8. Johnson DH, Strupp J, Greco FA, Hande KR, Hainsworth JD: Prolonged administration of oral etoposide in previously treated small cell lung cancer patients. Proc Amer Soc Clin Oncol 1990 (9): 227.

    Google Scholar 

  9. Clark PI, Cottier B, Joel SP, Thompson PI, Slevin ML: Prolonged administration of single agent oral etoposide in patients with untreated small cell lung cancer. Proc Amer Soc Clin Oncol 1990 (9):226.

    Google Scholar 

  10. Wolf SN, Johnson DH, Hande KR, Hainsworth JD, Greco FA: High dose etoposide as single agent chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep 1983 (67): 957–958.

    Google Scholar 

  11. Greco FA, Johnson DH, Hande KR, Porter LL, Hainsworth JD, Wolf SN: High dose etoposide (VP-16) in small cell lung cancer. Semin Oncol 1985 (12 Suppl 2):42–44.

    Google Scholar 

  12. Bradner WT, Rose WC and Huftalen JB: Antitumor activity of platinum analogs. In: Prestayko AW, Crooke ST and Carter SK (eds) Cisplatin — Current Status and New Development. Academic Press, New York 1980 pp 171–182.

    Google Scholar 

  13. Wolpert-Defelippes MK: Antitumor activity of cisplatin analogs. In: Prestayko AW, Crooke ST and Carter SK (eds) Cisplatin — Current Status and New Development. Academic Press, New York 1980 pp 193–212.

    Google Scholar 

  14. Wilkinson R, Cox PJ, Jones M and Harrap KR: Selection of potential second generation platinum compounds. Biochemie 1978 (60): 851–857.

    CAS  Google Scholar 

  15. Lelieveld P: Preclinical studies on toxicity, antitumor activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur J Cancer Clin Oncol 1984 (20): 1087–1104.

    PubMed  CAS  Google Scholar 

  16. Harrap KR, Jones M, Wilkinson CR, Clink HM, Sparrow S, Mitchley B, Clarke S and Vessey A: Antitumour, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: Prestayko AW, Crooke ST and Carter SK (eds) Cisplatin — Current Status and New Developments. Academic Press, New York 1980 p 193.

    Google Scholar 

  17. Rose WC, Schurig JE, Bradner WT and Huftalen JB: Antitumour activity and toxicity of cis-diamminedicholoroplatinum II analogs. Cancer Treat Rep 1982 (66): 135–146.

    PubMed  CAS  Google Scholar 

  18. Calvert AH, Harland SJ, Newell DR et al: Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982 (9): 140–147.

    PubMed  CAS  Google Scholar 

  19. Joss RA, Kaplan S, Goldhirsch A et al: A phase I trial of cis-diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin, CBDCA, JM-8) with a single dose every five-week schedule. Invest New Drugs 1984 (2): 297–304.

    PubMed  CAS  Google Scholar 

  20. Koalier JM, Trump DL, Tutsch KD, Earhartt RH, Davis TE, and Tormey DC: Phase I clinical trial and pharma-cokinetics of carboplatin by single monthly 30 minute infusion. Cancer 1986 (57): 22.

    Google Scholar 

  21. Van Echo DA, Egorin MJ, Whitacre MY et al: Phase I and pharmacologic trial of carboplatin daily for 5 days. Cancer Treat Rep 1984 (68): 1103–1114.

    PubMed  Google Scholar 

  22. Rosencwieg M, Nicaise C, Beer M et al: Phase I study of carboplatin (CBDCA) given on a 5 day intravenous schedule. J CLin Oncol 1983 (1): 621–626.

    Google Scholar 

  23. Gore ME, Calvert AH and Smith IE: High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. Eur J Cancer 1987 (23): 1391–1397.

    CAS  Google Scholar 

  24. Smith IE, Harland SJ, Robinson BA, Evans BD, Goodhart LC, Calvert AH, Yarnold J, Glees JP, Baker J and Ford HT: Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 1985 (69): 43–46.

    PubMed  CAS  Google Scholar 

  25. Jacobs RH, Bitran JD, Deutsch M, Hoffman PC, Sinkule J, Purl S and Golomb HM: Phase II study of carboplatin in previously untreated patients with metastatic small cell lung cancer. Cancer Treat Rep 1987 (71):311–312.

    PubMed  CAS  Google Scholar 

  26. Olver IN, Donehower RC, Van Echo DA, Ettinger DS and Aisner J: Phase II trial of carboplatin in non-small cell lung cancer. Cancer Treat Rep 1986 (70):421–422.

    PubMed  CAS  Google Scholar 

  27. Kreisman H, Ginsberg S, Propert KJ, Richards F, Griaziano S and Green M: Carboplatin or iproplatin in advanced non-small cell lung cancer: a cancer and leukemia group study. Cancer Treat Rep 1987 (71): 1049–1052.

    PubMed  CAS  Google Scholar 

  28. Mbidde EK, Harland SJ, Calvert AH and Smith IE: Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986 (18): 284–285.

    PubMed  CAS  Google Scholar 

  29. Cantwell BMJ, Franks CR and Harris AL: A Phase II study of the platinum analogue JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother Pharmacol 1986 (18): 286–288.

    PubMed  CAS  Google Scholar 

  30. Raghavan D, Giantoutsos P, Bishop J, Lee J, Young I, Corte P, Bye P, McCaughan B: Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990 (8): 151–154.

    PubMed  CAS  Google Scholar 

  31. Smith IE, Evans BD, Gore ME, Repetto L, Yarnold JR and Ford HT: Carboplatin (paraplatin: JM8) and etoposide (VP16) as first-line combination therapy for small cell lung cancer. J CLin Oncol 1987 (5):185–189.

    PubMed  CAS  Google Scholar 

  32. Bishop JF, Raghavan D, Stuart-Harris R, Morstyn G et al: Carboplatin (CBDCA, JM-8) and (VP16-213) in previously untreated patients with small cell lung cancer. J Clin Oncol 1987 (5): 1574–1578.

    PubMed  CAS  Google Scholar 

  33. Luikart SD, Mitchell EP, Van Echo DA et al: Phase I/II trial of etoposide (VP-16) and carboplatin (CBDCA) in untreated extensive small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1988 (7):195.

    Google Scholar 

  34. Gatzemeier U, Hossfeld DK, Achterrath W et al: Carboplatin, vincristine, etoposide as first line treatment in small cell lung cancer. Proc Am Soc Clin Oncol 1988 (7):201.

    Google Scholar 

  35. Bishop JF, Kefford R, Raghavan D, Zlacberg J et al: Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small cell lung cancer. Cancer Chemother Pharmacol 1990 (25): 367–370.

    PubMed  CAS  Google Scholar 

  36. Thatcher N, Lind M, Stout R, Payne C et al: Carboplatin, ifosfamide and etoposide with midcourse vincristine and thoracic radiotherapy for ‘limited’ stage small cell carcinoma of the bronchus. Br J Cancer 1989 (60):98–101.

    PubMed  CAS  Google Scholar 

  37. Albain KS, Crowley JJ, Le Blanc M, Livingston RB: Determinants of improved outcome in small cell lung cancer: an analysis of the 2580 patient Southwest Oncology Group Data Base. J. Clin Oncol 1990 (8): 1563–1574.

    CAS  Google Scholar 

  38. Lyss A, Perry M, Propert K and Green M: Etcposide carboplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1988 (7): 206.

    Google Scholar 

  39. Klastersky T, Soulier JP, Lacroix H, Dabouis G et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer. European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990 (8):1556–1562.

    PubMed  CAS  Google Scholar 

  40. Hellenic Cooperative Oncology Group (HECOG) and Lung Cancer Hellenic Study Group: Cisplatinum and etoposide vs carboplatinum and etoposide in small cell lung cancer (SCLC) patients (preliminary results). Ann Oncol 1990 (1 suppl):56 abstr 7:24.

    Google Scholar 

  41. Sarosy G: Ifosphamide — Pharmacologic overview. Semin. Oncol 1989 (16 suppl 3):2–8.

    Google Scholar 

  42. Johnson DH: Overview of Ifosphamide in small cell and non-small cell lung cancer. Semin Oncol 1990 (17 Suppl 4):24–30.

    Google Scholar 

  43. Warenius HM, Harman DC, Coltier B: High dose ifosphamide in small cell lung cancer. Br J Cancer 1986 (54): 216 (abstract).

    Google Scholar 

  44. Drings P: Ifosfamide in the treatment of bronchial carcinoma. Contr Oncol 1987 (26): 294–318.

    Google Scholar 

  45. Loehrer PJ, Birch R, Kramer BS et al: Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: A Southeastern Cancer Study Group trial. Cancer Treat Rep 1986 (70): 919–920.

    PubMed  Google Scholar 

  46. Morgan LR, Psey LE, Rainey J et al: Ifosfamide: A weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 1981 (65): 692–695.

    Google Scholar 

  47. Cantwell BMJ, Bozzino JM, Corris P et al: The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin, and vincristine (VPAV) for small cell lung cancer. Eur J Cancer Clin Oncol 1988 (24):123–129.

    PubMed  CAS  Google Scholar 

  48. Costanzi JJ, Morgan LR, Hokanson J: Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. Semin Oncol 1982 (9 suppl):61–65.

    Google Scholar 

  49. Holoye PY, Duelge J, Hansen RM et al: Prophylaxis of ifosfamide toxicity with oral acetylcysteine. Semin Oncol 1983 (10 Suppl 1): 66–71.

    Google Scholar 

  50. Loehrer PJ, Birch R, Kramer BS et al: Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: A South Eastern Cancer Study Group trial. Cancer Treat Rep 1986 (70): 919–920.

    PubMed  Google Scholar 

  51. Souhami KL, Spiro SG, Harper PG et al: Ifosfamide with and without mesna inoperable symptomatic non-small cell lung cancer. Presented at the IV World Conference on Lung Cancer, Toronto, Canada, 1985 (abstr 476).

    Google Scholar 

  52. Nobile MT, Rosso R, Brema F et al: Phase II study of ifosfamide combined with mesna uroprotection in advanced non-small cell lung cancer and other solid tumours. Tumori 1984 (70): 433–437.

    PubMed  CAS  Google Scholar 

  53. Harrison EF, Hawke JE, Hunter HL et al: Singledose ifosfamide: Efficacy studies in non-small cell lung cancer. Semin. Oncol 1982 (9 Suppl 1):56–60.

    Google Scholar 

  54. Peake MD, Parker D: Ifosfamide as single-agent chemotherapy in inoperable non-small cell lung cancer. Lancet 1985 (2): 496–497.

    PubMed  CAS  Google Scholar 

  55. Thatcher N, Anderson H, Smith DB et al: Ifosfamide by bolus as treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 1986 (18 suppl):30–33.

    Google Scholar 

  56. Tucker WG, Olayou-ho C: Preliminary evaluation of ifosfamide and 5-Fluorouracil in the treatment of 89 non-small cell carcinoma of the lung and adenocarcinoma of the ovary. 11th International Congress of Chemotherapy, Boston, 1979 p 1518 (abstract).

    Google Scholar 

  57. Thatcher N, Cerny T, Stout R et al: Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer 1987 (60): 2382–2387.

    PubMed  CAS  Google Scholar 

  58. Wolf M, Havemann K, Holle R et al: Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: A multicenter German randomized trial. J Clin Oncol 1987 (5): 1880–1889.

    PubMed  CAS  Google Scholar 

  59. Smith IE, Perren TJ, Ashley SA, Woodiwiss et al: Carboplatin, etoposide and ifosfamide as intensive chemotherapy for small cell lung carcinoma. J Clin Oncol 1990 (8):899–905.

    PubMed  CAS  Google Scholar 

  60. Drings P, Abel U, Bulzebruck H et al: Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer. Cancer Chemother Pharmacol 1986 (18 suppl 2): 34–39.

    Google Scholar 

  61. Shroeder M, Wellens W, Westerhausen M: Treatment of unresectable non-small cell lung cancer with cisplatinum, ifosfamide, vindesine. Contr Oncol 1987 (26): 369–371.

    Google Scholar 

  62. Ohnoshi T, Hiraki S, Ueoka H et al: Phase II study of a three-drug combination of ifosfamide, cisplatin, and vindesine in non-small cell lung cancer. Jpn J Cancer Chemother 1988 (15): 115–119.

    CAS  Google Scholar 

  63. Rosell R, Abad-Esteve A, Moreno I et al: A randomized comparison of two vindesine plus cisplatin containing regimens with the addition of mitomycin (MVP) or ifosfamide (IVP) in patients with non-small cell bronchogenic carcinoma. Presented at the 4th European Conference Clinical Oncology Cancer Nursing, 1987 (abstr).

    Google Scholar 

  64. Wellens W, Mussgnug G, Habets L et al: Ifosfamide and VP16-213 combination therapy in advanced non-small cell bronchogenic cancer. Presented at the 13th International Cancer Congress. 1982 p 9 (abstr).

    Google Scholar 

  65. Jain K, Casper ES, Geller NL et al: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985 (3): 818–826.

    PubMed  CAS  Google Scholar 

  66. Blastein M, Eisenhauer EA, Wierzbicki R, Yoshida S: Epirubicin in extensive small-cell lung cancer: A Phase II study in previously untreated patients: A National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 1990 (8): 385–389.

    Google Scholar 

  67. Ettinger DS: Evaluation of new drugs in untreated patients with small-cell lung cancer: its time has come. J Clin Oncol 1990 (8): 374–377.

    PubMed  CAS  Google Scholar 

  68. Ettinger DS, Finkelstein DM, Abeloff MD, Bonomi PD: Justification for evaluating new anticancer drugs in selected untreated patients with chemosensitive advanced cancer: an ECOG randomized study. Proc Amer Soc Clin Oncol 1990 (9): 224.

    Google Scholar 

  69. Evans WK, Eisenhauer EA, Larmier Y et al: Phase II study of amonafide: results of treatment and lessons learned from a study of an investigational agent in previously untreated patients with extensive small cell lung cancer. J Clin Oncol 1990 (8): 390–395.

    PubMed  CAS  Google Scholar 

  70. Buckner CD, Rudolph RH, Fefer A et al: High dose cyclophosphamide for malignant disease: toxicity, tumour response and effects of stored autologous marrow. Cancer 1972 (29): 357–365.

    Google Scholar 

  71. Gale RP, Graze PR, Wells J et al: Autologous bone marrow transplantation in patients with cancer. Experimental Hematol 1979 (7 suppl): 351–359.

    Google Scholar 

  72. Douer D, Champlin RE, Ho WG et al: High dose combined modality therapy and autologous bone marrow transplantation in resistant cancer. Amer J Med 1981 (71): 973–976.

    PubMed  CAS  Google Scholar 

  73. Spitzer G, Dickie KA, Litarr. M et al: High dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumour. Cancer 1980 (45): 3075–3085.

    PubMed  CAS  Google Scholar 

  74. Pico JL, Beanycan F, Delore M et al: High dose chemotherapy with autologous bone marrow transplantation in small cell lung cancer in relapse. Proc Amer Soc Clin Oncol 1983: c 806.

    Google Scholar 

  75. Harada M, Yoshida T, Funada H et al: Combined modality therapy and autologous bone marrow transplantation in the treatment of advanced Non-Hodgkin’s lymphoma and solid tumour: the Kanazawa Experience Transplantation Proceedings 1982 (14): 733–737.

    PubMed  CAS  Google Scholar 

  76. Stewart P, Buchner CD, Thomas ED et al: Intensive chemo-radiotherapy with autologous bone marrow transplantation of small cell carcinoma of the lung. Cancer Treat. Rep 1983 (67): 1055–1059.

    CAS  Google Scholar 

  77. Stahel RA, Takvonan RW, Skarin AT, Canellos GP: Autologous bone marrow transplantation following high dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung a review of current literature. Eur J Clin Oncol 1984 (20): 1233–1238.

    CAS  Google Scholar 

  78. Cunningham D, Banham SW, Hutcheon AH et al: High dose cyclophosphamide and VP16 as late dosage intensification therapy for small cell carcinoma of the lung. Cancer Chemother Pharmacol 1985 (15): 303–306.

    PubMed  CAS  Google Scholar 

  79. Smith IE, Evans BD, Harland SJ et al: High dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung cancer. Cancer Chemother Pharmacol 1985 (14): 120–124.

    PubMed  CAS  Google Scholar 

  80. Scullier JP, Klastenky J, Stryckmans P and The ADATC Lung Cancer Working Party: Late intensification in small cell lung cancer: A Phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation. J Clin Oncol 1985 (3): 184–191.

    Google Scholar 

  81. Dickie KA, Spitzer G: Evaluation of the use of high dose cytoreduction with autologous bone marrow rescue in various malignancies. Transplantation 1986 (41):4–20.

    Google Scholar 

  82. Idhe DC, Deissroth AB, Lichter AS, et al: Late intensive combined modality therapy followed by autologous bone marrow infusion in extensivestage small cell lung cancer. J Clin Oncol 1986 (4):1443–1454.

    Google Scholar 

  83. Souhami RL, Hajichristou HT, Miles DW et al: Intensive chemotherapy with autologous bone marrow transplantation of small cell lung cancer. Cancer Chemother Pharmacol 1989 (24): 321–325.

    PubMed  CAS  Google Scholar 

  84. Marangolo M, Rosti G, Amadori D et al: High dose etoposide and autologous bone marrow transplantation as intensification treatment in small cell lung cancer: a pilot study. Bone Marrow Transpl 1989 (4): 405–408.

    CAS  Google Scholar 

  85. Humblet Y, Symann M, Bosly A et al: Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung: a randomized study. J Clin Oncol 1987 (5): 1864–1873.

    PubMed  CAS  Google Scholar 

  86. Harrap KR: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985 (12): 21–33.

    PubMed  CAS  Google Scholar 

  87. Rose WC, Schurig JE: Preclinical antitumour and toxicologic profile of carboplatin. Cancer Treat Rev 1985 (12): 1–19.

    PubMed  CAS  Google Scholar 

  88. Ozols RF, Ostetega Y, Curt G, Young RC: High dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 1987 (5): 197–201.

    PubMed  CAS  Google Scholar 

  89. Elder JP, Shea TL, Henner WD, Elias AD, Teicher BA, Weissman L, Wheeler CA, Ayash L, Schmyber SM, Deary J, Schimpper LE, Fur E, Antman KH: High dose combination alkylating agent therapy with carboplatin and autologous bone marrow transplantation in solid tumours. In: Burns, Canetta, Ozols, Rosenweig (eds) Carboplatin (JM-8): Current Perspectives and Future Directions. Saunders, Philadelphia 1990 pp 353–360.

    Google Scholar 

  90. Jones RB, Shapall EJ, Ross M, Coniglio D, Alphonti ML, Peters WP: High dose carboplatin, cyclophosphamide and BCNU with autologous bone marrow support, excessive hepatic toxicity. Cancer Chemother Pharmacol 1990 (26):155–156.

    PubMed  CAS  Google Scholar 

  91. Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlow J, Schrybar SM, Begg C, Teicher BA: High dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol 1990 (17 suppl 3): 33–38.

    Google Scholar 

  92. Egorin MJ, Van Echo DA, Tipping SJ et al: Pharmacokinetics and dosage reduction of cisdiammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Chemother Pharmacol 1984 (44):432–438.

    Google Scholar 

  93. Egorin MJ, Van Echo DA, Olman EA et al: Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclo-butane-dicarboxylatoplatinum. Cancer Res 1985 (45): 6502–6506.

    PubMed  CAS  Google Scholar 

  94. Calvert AH, Newell DR, Gumbrell LA, O’Reilly, Barnell M, Boxall FE, Siddik ZH, Johnson IR, Gore ME, Wiltshaw E: Carboplatin dosage prospective evaluation of a sample formula based on renal function. J Clin Oncol 1989 (7):1748–1756.

    PubMed  CAS  Google Scholar 

  95. Clark SC, Kamen R: The human hematopoietic colony-stimulating factors. Science 1987 (236):1229–1237.

    PubMed  CAS  Google Scholar 

  96. Golde DW, Gasson JC: Cytokines: Myeloid growth factors. In: Gallin JI, Goldstein IM, Snyderman R (eds) Inflammation: Basic Principles and Clinical Correlates. New York, Raven 1988 pp 253–261.

    Google Scholar 

  97. Golde DW, Gasson JC: Hormones that stimulate the growth of blood cells. Aci Am 1988 (259): 62–70.

    CAS  Google Scholar 

  98. Metcalf D: The granulocyte-macrophage colonystimulating factors. Science 1985 (229): 16–22.

    PubMed  CAS  Google Scholar 

  99. Morstyn G, Burgess AW: Hemopoietic growth factors: A review. Cancer Res 1988 (48):5624–5637.

    PubMed  CAS  Google Scholar 

  100. Sachs L: The molecular control of blood cell development. Science 1987 (238): 1374–1379.

    PubMed  CAS  Google Scholar 

  101. Sieff CA: Hematopoietic growth factors. J Clin Invest 1987 (79): 1549–1557.

    PubMed  CAS  Google Scholar 

  102. Antman KS, Griffin JD, Elias A et al: Effect of recombinant human granulocyte-macrophage colony stimulating factor on chemotherapy-induced myelo-suppression. New Engl J Med 1988 (319): 593–598.

    PubMed  CAS  Google Scholar 

  103. Brandt SJ, Peters WP, Atwater SK et al: Effect of recombinant granulocyte-macrophage colony stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. New Engl J Med 1988 (318):869–876.

    PubMed  CAS  Google Scholar 

  104. Nemunaitis J, Singer JW, Buckner CD et al: Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988 (72): 834–836.

    PubMed  CAS  Google Scholar 

  105. Sheridan W, Morstyn G, Green M, Boyd A et al: Phase II study of granulocyte colony stimulating factor in autologous bone marrow transplantation. Proc Amer Sci Clin Oncol 1989:8178 (abstract).

    Google Scholar 

  106. Morstyn G, Stuart-Harris R, Bishop J, Raghavan D et al: Optimal scheduling of granulocyte-macrophage colony stimulating factor (GM-CSF) for the abrogator of chemotherapy induced neutropenia in small cell lung cancer. Proc Amer Soc Clin Oncol 1989 (8):219 (abstract).

    Google Scholar 

  107. Gabrilove JL, Jakubowski A, Scher H et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. New Engl J Med 1988 (381):1414–1422.

    Google Scholar 

  108. Crawford J, Ozen H, Johnson D: Granulocyte colony stimulating factor: prevention of chemotherapy induced febrile neutropenia in patients with small cell lung cancer. Proc Amer Soc Clin Oncol 1990 (9):229 (abstract).

    Google Scholar 

  109. Joss RA, Cavalli F, Goldhursch A et al: New drugs in small cell lung cancer. Cancer Treat Rev 1986 (13):157–176.

    PubMed  CAS  Google Scholar 

  110. Olesen BR, Ernst P, Nissen MH, Hansen HH: Recombinant interferon. A therapy in small cell and squamous cell carcinoma of the lung. A phase II study. Eur J Cancer 1987 (23):987–989.

    CAS  Google Scholar 

  111. Newham HF, Blecher NM, Galazka A, Scott E: Small cell lung carcinoma. A phase II evaluation of r-interferon-gamma. Cancer 1987 (60):2938–40.

    Google Scholar 

  112. Ettinger DS, Harwood K: Phase II study of recombinant beta interferon in patients with advanced non-small cell lung carcinoma. Med Pediatr Oncol 1988 (16):30–32.

    PubMed  CAS  Google Scholar 

  113. Giaccone G, Donado M, Bonardi G et al: Phase II study of alpha-interferon plus bleomycin in advanced non-small cell lung cancer. Anticancer Res 1989 (9):405–408.

    PubMed  CAS  Google Scholar 

  114. Rosenberg SA, Lotze MT, Muul LM et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987 (316):889–897.

    PubMed  CAS  Google Scholar 

  115. Rosenberg SA, Packard BB, Acbersold PM et al: Immunotherapy of patients with metastatic melanoma using tumour infiltrating lymphocytes and interleukin-2. N Engl J Med 1988 (319):1676–1680.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, 481 Little Lonsdale Street, Melbourne, Victoria, 3000, Australia

    James F. Bishop

Authors
  1. James F. Bishop
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Colorado Cancer Center, 4200 East Ninth Avenue, Denver, CO, 80262, USA

    Paul A. Bunn Jr. M. D. (Professor of Medicine and Director) (Professor of Medicine and Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Bishop, J.F. (1991). Future Directions in the Therapy of Lung Cancer. In: Bunn, P.A. (eds) Current Topics in Lung Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76784-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76784-5_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76786-9

  • Online ISBN: 978-3-642-76784-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation